RE:RE:RE:RE:RE:RE:Roger buying againGlad you noticed it Fred ... ;-)
It indeed confirms that they have a deal with PHAC and that our anti-virus platform shows enough impressive efficacy ratios, that they could move faster on this one. So the PHAC Dr. Kobasa's comment on a
canadian-made vaccine and flexible platform
against many types of viruses (H1N1 Influenza, Zika, Herpes Simplex and Corona viruses - Biological Safety Level (“BSL”) 2 and 3). The flexibility of our platform interests the canadian government.
BioNtech was first launched to address cancer but never developed it. They moved in 2018 to anti-virus (influenza/Zike, etc ...) via a deal with Pfizer and then jumped on the COVID-19 opportunity. Now, they're trying to come back to cancer (but they're not addressing the destruction of solid tumors like we are).
So TLT management decided that COVID-19 was less risky and would take less time to get valuation, over the risky GBM indication that requires long follow-ups. But they will proceed with NSCLC, the #1 cancer in both the US and Canada. 20x more lung cancer cases than GBM ones.
So we would prove efficient on 2 different types of platforms:
- oncology (NMIBC, NSCLC (and GBM in preclinical))
- anti-virus (COVID-19 is now a reality (6th wave) and not going away anytime soon and anti-viruses platforms are rare, governments have noticed)
That would be managing the risk, when you read the following stats:
The American Cancer Society’s estimates for lung cancer in the United States for 2022 are:
- About 236,740 new cases of lung cancer (117,910 in men and 118,830 in women)
- About 130,180 deaths from lung cancer (68,820 in men and 61,360 in women)
Lung cancer is by far the leading cause of cancer death , making up almost 25% of all cancer deaths. Each year, more people die of lung cancer than of colon, breast, and prostate cancers combined. Glioblastoma Facts & Figures
- Glioblastoma (or GBM) is one of the most complex, deadly, and treatment-resistant cancers.
- More than 13,000 Americans are expected to receive a GBM diagnosis in 2020.
- GBM accounts for 48% of all primary malignant brain tumors.
- It is estimated that more than 10,000 individuals in the United States will succumb to glioblastoma every year.
- The five-year survival rate for glioblastoma patients is only 6.8%, and the average length of survival for glioblastoma patients is estimated to be only 12 to 18 months.
- Survival rates and mortality statistics for GBM have been virtually unchanged for decades.
- Despite first being identified in the scientific literature in the 1920’s, there have only been four drugs and one device ever approved by the FDA for the treatment of glioblastoma.
- None of these treatments have succeeded in significantly extending patient lives beyond a few extra months.
- Some patients have a glioblastoma upon diagnosis (de novo or primary GBM), while other patients’ tumors start as another, lower-grade type of brain tumor and over time progress into a glioblastoma (secondary GBM). A vast majority of GBM diagnoses are de novo.
- Mean age at diagnosis is 64.
- In addition to being life-threatening, GBM – and its harsh treatments – inflict devastation upon the brain, which controls cognition, mood, behavior, and every function of every organ and body part.
- Many patients will lose their ability to work, drive, and a host of other functions that contribute to one’s sense of self and independence.
- Glioblastoma is also one of the more expensive cancers to treat, often leaving patients and families with major financial hardship on top of the burdens of the disease.
____________________
fredgoodwinson - (4/18/2022 3:46:43 PM)
RE:RE:RE:RE:RE:Roger buying again
GBM no longer on the agenda Laser (Presentation 7 Feb 2022)